|
1
|
William DF, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Eng J Med. 363:1938–1948. 2010.
View Article : Google Scholar
|
|
2
|
Cinkaya A, Akin M and Sengul A: Evaluation
of treatment outcomes of triple-negative breast cancer. J Cancer
Res Ther. 12:150–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gu G, Dustin D and Fuqua SA: Targeted
therapy for breast cancer and molecular mechanisms of resistance to
treatment. Curr Opin Pharmacol. 31:97–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee A and Djamgoz MBA: Triple negative
breast cancer: Emerging therapeutic modalities and novel
combination therapies. Cancer Treat Rev. 62:110–122. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Creighton CJ, Li X, Landis M, Dixon JM,
Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A,
Herschkowitz JI, et al: Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating features.
Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimbung S, Markholm I, Bjöhle J, Lekberg
T, von Wachenfeldt A, Azavedo E, Saracco A, Hellstrom M, Veerla S,
Paquet E, et al: Assessment of early response biomarkers in
relation to long-term survival in patients with HER2-negative
breast cancer receiving neoadjuvant chemotherapy plus bevacizumab:
Results from the Phase II PROMIX trial. Int J Cancer. 142:618–628.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonotto M, Gerratana L, Poletto E, Driol
P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa
FE, et al: Measures of outcome in metastatic breast cancer:
Insights from a real-world scenario. Oncologist. 19:608–615. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wali VB, Langdon CG, Held MA, Platt JT,
Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF and Hatzis
C: Systematic drug screening identifies tractable targeted
combination therapies in triple-negative breast cancer. Cancer Res.
77:566–578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang S, Zhang H, Ghia EM, Huang J, Wu L,
Zhang J, Lam S, Lei Y, He J, Cui B, et al: Inhibition of
chemotherapy resistant breast cancer stem cells by a ROR1 specific
antibody. Proc Natl Acad Sci. 116:1370–1377. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pavlopoulou A, Oktay Y, Vougas K, Louka M,
Vorgias CE and Georgakilas AG: Determinants of resistance to
chemotherapy and ionizing radiation in breast cancer stem cells.
Cancer Lett. 380:485–493. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dittmer J: Breast cancer stem cells:
Features, key drivers and treatment options. Semin Cancer Biol.
53:59–74. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baccelli I, Schneeweiss A, Riethdorf S,
Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T,
Wallwiener M, et al: Identification of a population of blood
circulating tumor cells from breast cancer patients that initiates
metastasis in a xenograft assay. Nat Biotechnol. 31:539–544. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pattabiraman DR and Weinberg RA: Tackling
the cancer stem cells-what challenges do they pose? Nat Rev Drug
Discov. 13:497–512. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peitzsch C, Tyutyunnykova A, Pantel K and
Dubrovska A: Cancer stem cells: The root of tumor recurrence and
metastases. Semin Cancer Biol. 44:10–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qi F, Li A, Zhao L, Inagaki Y, Wang D, Cui
X, Gao B, Kokudo N, Nakata M and Tang W: Cinobufacini, an aqueous
extract from Bufobufogargarizans Cantor, induces apoptosis through
a mitochondria-mediated pathway in human hepatocellular carcinoma
cells. J Ethnopharmacol. 128:654–661. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Calderón-Montaño JM, Burgos-Morón E, Orta
ML, Maldonado-Navas D, García-Domínguez I and López-Lázaro M:
Evaluating the cancer therapeutic potential of cardiac glycosides.
Biomed Res Int. 2014:7949302014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lan YL, Lou JC, Jiang XW, Wang X, Xing JS,
Li S and Zhang B: A research update on the anticancer effects of
bufalin and its derivatives. Oncol Lett. 17:3635–3640.
2019.PubMed/NCBI
|
|
18
|
Cheng CS, Wang J, Chen J, Kuo KT, Tang J,
Gao H, Chen L, Chen Z and Meng Z: New therapeutic aspects of
steroidal cardiac glycosides: The anticancer properties of
Huachansu and its main active constituent bufalin. Cancer Cell Int.
19:922019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song X, Zhang C, Zhao M, Chen H, Liu X,
Chen J, Lonard DM, Qin L, Xu J, Wang X, et al: Steroid receptor
coactivator-3 (SRC-3/AIB1) as a novel therapeutic target in triple
negative breast cancer and its inhibition with a phospho-bufalin
prodrug. PLoS One. 10:e01400112015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Li C, Zhu Z, Teng Y, Che X, Wang
Y, Ma Y, Wang Y, Zheng H, Liu Y and Qu X: miR-155-5p antagonizes
the apoptotic effect of bufalin in triple-negative breast cancer
cells. Anticancer Drugs. 27:9–16. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takai N, Kira N, Ishii T, Yoshida T,
Nishida M, Nishida Y, Nasu K and Narahara H: Bufalin, a traditional
oriental medicine, induces apoptosis in human cancer cells. Asian
Pac J Cancer Prev. 13:399–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Xia Y, Zuo Q and Chen T: Molecular
mechanisms underlying the antimetastatic activity of bufalin. Mol
Clin Oncol. 8:631–636. 2018.PubMed/NCBI
|
|
23
|
Zhao L, Liu S, Che X, Hou K, Ma Y, Li C,
Wen T, Fan Y, Hu X, Liu Y and Qu X: Bufalin inhibits TGF-β-induced
epithelial-to-mesenchymal transition and migration in human lung
cancer A549 cells by downregulating TGF-β receptors. Int J Mol Med.
36:645–652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng Y, Chen Y, Meng Y, Cao Q, Liu Q, Ling
C and Wang C: Bufalin suppresses migration and invasion of
hepatocellular carcinoma cells elicited by poly (I:C) therapy.
Oncoimmunology. 7:e14264342018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yao GD, Niu YY, Chen KX, Meng HX, Yao GD,
Song HT, Tian ZN, Geng JS and Feng MY: SOX2 gene expression and its
role in triple negative breast cancer tissues. J Biol Regul Homeost
Agents. 32:1399–1406. 2018.PubMed/NCBI
|
|
26
|
Zhang JM, Wei K and Jiang M: OCT4 but not
SOX2 expression correlates with worse prognosis in surgical
patients with triple-negative breast cancer. Breast Cancer.
25:447–455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu P, Tang H, Song C, Wang J, Chen B,
Huang X, Pei X and Liu L: SOX2 promotes cell proliferation and
metastasis in triple negative breast cancer. Front Pharmacol.
9:9422018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L,
Song N, Teng Y and Liu Y: Downregulation of Cbl-b by bufalin
results in up-regulation of DR4/DR5 and sensitization of
TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin
Oncol. 138:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clifford RJ and Kaplan JH: Human breast
tumor cells are more resistant to cardiac glycoside toxicity than
non-tumorigenic breast cells. PLoS One. 8:e843062013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hsu CM, Tsai Y, Wan L and Tsai FJ: Bufalin
induces G2/M phase arrest and triggers autophagy via the TNF, JNK,
BECN-1 and ATG8 pathway in human hepatoma cells. Int J Oncol.
43:338–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Yu X, Guo H, Sun L, Wang A, Liu Q,
Wang X and Li J: Bufalin exerts antitumor effects by inducing cell
cycle arrest and triggering apoptosis in pancreatic cancer cells.
Tumour Biol. 35:2461–2471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gai JQ, Sheng X, Qin JM, Sun K, Zhao W and
Ni L: The effect and mechanism of bufalin on regulating
hepatocellular carcinoma cell invasion and metastasis via
Wnt/β-catenin signaling pathway. Int J Oncol. 48:338–348. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qian L, Su H, Wang G, Li B, Shen G and Gao
Q: Anti-tumor activity of bufalin by inhibiting c-MET mediated
MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer. J
Cancer. 11:3114–3123. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Peto R, Davies C, Godwin J, Gray R,
Pan HC, Clarke M, Cutter D, Darby S, McGale P, et al: Comparisons
between different polychemotherapy regimens for early breast
cancer: meta-analyses of long-term outcome among 100,000 women in
123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Adorno-Cruz V, Kibria G, Liu X, Doherty M,
Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M,
et al: Cancer stem cells: Targeting the roots of cancer, seeds of
metastasis, and sources of therapy resistance. Cancer Res.
75:924–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Phi LTH, Sari IN, Yang YG, Lee SH, Jun N,
Kim KS, Lee YK and Kwon HY: Cancer stem cells (CSCs) in drug
resistance and their therapeutic implications in cancer treatment.
Stem Cells Int. 2018:54169232018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cojoc M, Mabert K, Muders MH and Dubrovska
A: A role for cancer stem cells in therapy resistance: Cellular and
molecular mechanisms. Semin Cancer Biol. 31:16–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ,
Gimotty PA, Guerra M, Guo W and Xu X: Acquired cancer stem cell
phenotypes through Oct4-mediated dedifferentiation. Oncogene.
31:4898–4911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moon JH, Kwon S, Jun EK, Kim A, Whang KY,
Kim H, Oh S, Yoon BS and You S: Nanog-induced dedifferentiation of
p53-deficient mouse astrocytes into brain cancer stem-like cells.
Biochem Biophys Res Commun. 412:175–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shachaf CM, Kopelman AM, Arvanitis C, et
al: MYC inactivation uncovers pluripotent differentiation and
tumour dormancy in hepatocellular cancer. Nature. 431:1112–1117.
2004. View Article : Google Scholar : PubMed/NCBI
|
